axitinib,pembrolizumab,Nivolumab,ipilimumab
pfizer,merck,BMS
['nivo', 'ipi/', 'pembro']
 real-world analysis of pembro/axi vs ipi/nivo (n=764) 12-mo os: 86% vs 78% (p&lt;0.001) in favor of pembro/axi 24-mo os: 68% vs 65% (p=0.52) hospitalization rates 3 mo post-treatment: 32% for ipi/nivo vs 20% for pembro/axi #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧